Cendakimab is safe and efficacious in treating moderate-to-severe AD in adult patients.

Patients with moderate-to-severe PsO are more than twice as likely to take a half-day off work than those with mild psoriasis

Last year's recipients of the Canadian Skin of Colour Diversity Scholarship award discuss their projects and reasons to apply.

White rosacea patients have an increased risk for malignant melanoma than non-White patients.

There is a significant autoimmune disease prevalence in psoriasis patients

A fixed-dose, triple-combination CAB topical formulation demonstrated efficacy and safety in both adult and pediatric patients with acne.

Older age is linked to shorter intervals between the diagnosis of PsO and PsA.

AD patients have an increased risk of impaired mobility if they are male or aged 40 to 59 years.